Payment overview · 2025
General Payments
$291.27
13 reported records · 9 companies
Healthcare provider profile · identity verified
Gilbert Sunio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VISALIA, CA · NPI 1972500577
Verified facts
What the public records show
CMS Open Payments records show Gilbert Sunio, M.D. received $291.27 in general payments during 2025 across 13 reported records.
Verity Pharmaceuticals Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.39 | 23.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.29 | 21.0% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $34.54 | 11.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.14 | 9.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $23.79 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.72 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.64 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.35 | 6.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.41 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.27 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $69.39 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $34.54 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $34.54 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 547 | 154 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 339 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 78 |
| Celecoxib | Celecoxib | 249 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 67 |
| Lisinopril | Lisinopril | 230 | 63 |
| Losartan Potassium | Losartan Potassium | 204 | 54 |
| Metformin Hcl | Metformin Hcl | 197 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 53 |
| Alprazolam | Alprazolam | 187 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 51 |
| Gabapentin | Gabapentin | 157 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 45 |
| Omeprazole | Omeprazole | 136 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 20 |
| Furosemide | Furosemide | 118 | 26 |
| Simvastatin | Simvastatin | 109 | 31 |
| Glimepiride | Glimepiride | 107 | 27 |
| Sertraline Hcl | Sertraline Hcl | 102 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 25 |
| Donepezil Hcl | Donepezil Hcl | 90 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 13 |
| Tramadol Hcl | Tramadol Hcl | 81 | 24 |
| Ozempic | Semaglutide | 79 | 16 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Eliquis | Apixaban | 76 | 13 |
| Sulindac | Sulindac | 75 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 60 |
| Lorazepam | Lorazepam | 71 | 20 |
| Atenolol | Atenolol | 70 | 17 |
| Allopurinol | Allopurinol | 69 | 22 |
| Memantine Hcl | Memantine Hcl | 68 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 24 |
| Prednisone | Prednisone | 65 | 49 |
| Baclofen | Baclofen | 62 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Meloxicam | Meloxicam | 53 | 17 |
| Trazodone Hcl | Trazodone Hcl | 53 | 15 |
| Carvedilol | Carvedilol | 52 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Propranolol Hcl | Propranolol Hcl | 46 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 11 |
| Linzess | Linaclotide | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 17 |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 26 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.27 · 13 records | Verity Pharmaceuticals Inc. | CONTRAVE, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, JATENZO, MOUNJARO, NURTEC ODT, Tlando, Wegovy, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error